Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Mosipasertib - Atrin Pharmaceuticals

Next Previous
Drug Profile

Mosipasertib - Atrin Pharmaceuticals

Alternative Names: ATRN 119

Latest Information Update: 08 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atrin Pharmaceuticals
  • Class Antineoplastics; Macrocyclic compounds; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 01 Jun 2026 Washington University School of Medicine in collaboration with Aprea Therapeutics plans a phase I trial for Acute myeloid leukemia and Myelodysplastic syndromes (Combination therapy) in USA (PO) (NCT07617363)
  • 11 May 2026 Aprea Therapeutics in collaboration with University of Pennsylvania plans a phase I/II trial for Squamous cell carcinoma (Neoadjuvant therapy, Early stage disease) in May 2026 (PO) (NCT07578467)
  • 09 Mar 2026 Aprea Therapeutics completes a phase I/II ABOYA-119 trial in Solid tumours (In adolescents, In adults, In the elderly, Late-stage disease) in USA (PO) (NCT04905914)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top